Litton Mark James bought ATHA
December 31, 2025 · Form 4 insider transaction
Litton Mark James bought 10,834 shares of Athira Pharma, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 5 days after the transaction.
Direction
Acquired (buy-side)
Shares
10,834
Price
$0.00
Total value
N/A
InsiderLitton Mark James
RoleOfficer, Director
CompanyAthira Pharma, Inc. (ATHA)
SecurityCommon Stock
Transaction codeM: Option exercise
Transaction dateDecember 31, 2025
Filing dateJanuary 5, 2026
Shares owned after43,414
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The reported number of shares in this Form 4 has been adjusted to reflect the impact of the Issuer's 10-for-1 reverse stock split completed on September 17, 2025 (the "Reverse Stock Split").